700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Research Article Open Access
A number of infectious disease treatments are available today. However, infectious diseases still pose serious threats to patients because of the development of antibiotic resistance and the emergence of new infectious diseases. As on date, about 400 drugsincluding New Chemical Entities (NCEs), biologics, vaccines, new dosage forms and drug combinations areat different phases of their development (pre-clinical, Phase I, Phase II, Phase III or preregistration phase) against infectious diseases. This article provides preliminary information about New Chemical Entities (NCEs) for which New Drug Application (NDA) has been submitted by pharmaceutical companies to Food and Drug Administration (FDA) or which are in Phase III of their clinical trial. It would be interesting to see how many of New Chemical Entities (NCEs), among those discussed in this article, will see the face of the future.
To read the full article Peer-reviewed Article PDF
Author(s): Abida Mohd Imran Mohamed A M Hagga and Said A ElFeky
New Chemical Entities (NCEs), Infectious Diseases, Clinical Trial, U.S. Food and Drug Administration (FDA) and New Drug Application (NDA).